PMID- 28195035
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20211204
IS  - 1555-3892 (Electronic)
IS  - 0963-6897 (Print)
IS  - 0963-6897 (Linking)
VI  - 26
IP  - 3
DP  - 2017 Mar 13
TI  - Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential 
      Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma.
PG  - 429-438
LID - 10.3727/096368916X694382 [doi]
AB  - Chronic hepatitis B virus (HBV) infection is a major risk factor for 
      hepatocellular carcinoma (HCC). Pre-S2 mutant represents an HBV oncoprotein that 
      is accumulated in the endoplasmic reticulum (ER) and manifests as type II ground 
      glass hepatocytes (GGHs). Pre-S2 mutant can induce ER stress and initiate 
      multiple ER stress-dependent or -independent cellular signal pathways, leading to 
      growth advantage of type II GGH. Importantly, the mammalian target of rapamycin 
      (mTOR) signal pathways are consistently activated throughout the liver 
      tumorigenesis in pre-S2 mutant transgenic mice and in human HCC tissues, leading 
      to hepatocyte proliferation, metabolic disorders, and HCC tumorigenesis. In this 
      review, we summarize the pre-S2 mutant-induced mTOR signal pathways and its 
      implications in HBV-related HCC tumorigenesis. Clinically, the presence of pre-S2 
      mutant exhibits a high resistance to antiviral treatment and carries a high risk 
      of HCC development in patients with chronic HBV infection. Targeting at pre-S2 
      mutant-induced mTOR signal pathways may thus provide potential strategies for the 
      prevention or therapy of HBV-associated HCC.
FAU - Teng, Chiao-Fang
AU  - Teng CF
FAU - Wu, Han-Chieh
AU  - Wu HC
FAU - Shyu, Woei-Cherng
AU  - Shyu WC
FAU - Jeng, Long-Bin
AU  - Jeng LB
FAU - Su, Ih-Jen
AU  - Su IJ
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170214
PL  - United States
TA  - Cell Transplant
JT  - Cell transplantation
JID - 9208854
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Carcinoma, Hepatocellular/genetics/*metabolism/*virology
MH  - Hepatitis B virus/*pathogenicity
MH  - Hepatocytes/metabolism
MH  - Humans
MH  - Liver Neoplasms/genetics/metabolism/virology
MH  - Signal Transduction/genetics/physiology
MH  - TOR Serine-Threonine Kinases/genetics/*metabolism
PMC - PMC5657708
EDAT- 2017/02/15 06:00
MHDA- 2017/11/29 06:00
PMCR- 2017/03/01
CRDT- 2017/02/15 06:00
PHST- 2017/02/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/02/15 06:00 [entrez]
PHST- 2017/03/01 00:00 [pmc-release]
AID - 10.3727_096368916X694382 [pii]
AID - 10.3727/096368916X694382 [doi]
PST - ppublish
SO  - Cell Transplant. 2017 Mar 13;26(3):429-438. doi: 10.3727/096368916X694382. Epub 
      2017 Feb 14.